Search

Background Hypertension and diabetes cause chronic kidney disease (CKD) and diastolic left ventricular dysfunction (DVD) as forerunners of disability and death. Home blood pressure telemonitoring (HTM) and urinary peptidomic profiling (UPP) are technologies enabling prevention. Methods UPRIGHT-HTM (Urinary Proteomics Combined with Home Blood Pressure Telemonitoring for Health Care Reform [NCT04299529]) is an investigator-initiated 5-year clinical trial with patient-centred design, which will randomise 1148 patients to be recruited in Europe, sub-Saharan Africa and South America. During the whole study, HTM data will be collected and freely accessible for patients and caregivers. The UPP, measured at enrolment only, will be communicated early during follow-up to 50% of patients and their caregivers (intervention), but only at trial closure in 50% (control). The hypothesis is that early knowledge of the UPP risk profile will lead to more rigorous risk factor management and result in benefit. Eligible patients, aged 55-75 years old, are asymptomatic, but have >= 5 CKD- or DVD-related risk factors, preferably including hypertension, type-2 diabetes, or both. The primary endpoint is a composite of new-onset intermediate and hard cardiovascular and renal outcomes. Demonstrating that combining UPP with HTM is feasible in a multicultural context and defining the molecular signatures of early CKD and DVD are secondary endpoints. Expected outcomes The expected outcome is that application of UPP on top of HTM will be superior to HTM alone in the prevention of CKD and DVD and associated complications and that UPP allows shifting emphasis from treating to preventing disease, thereby empowering patients. The authors gratefully acknowledge the enthusiasm of the patientsenrolled in UPRIGHT-HTM and the expert assistance of the consul-tants, residents and nursing staff supporting the trial at the clinicalsites. The Alliance for the Promotion of Preventive Medicine is anot-profitresearchinstitute(URL:www.appremed.org;Belgianregis-trationnumber,739849385),whichreceivedanon-bindinggrantfromOMRONHealthcareCo.Ltd.,Kyoto,Japan.UPRIGHT-HTMisaTopZprojectsupportedbyOMRONHealthcareCo.Ltd.,Kyoto,Japan

Background: Whether cardiovascular risk is more tightly associated with central (cSBP) than brachial (bSBP) systolic pressure remains debated, because of their close correlation and uncertain thresholds to differentiate cSBP into normotension versus hypertension. Methods: In a person-level meta-analysis of the International Database of Central Arterial Properties for Risk Stratification (n=5576; 54.1% women; mean age 54.2 years), outcome-driven thresholds for cSBP were determined and whether the cross-classification of cSBP and bSBP improved risk stratification was explored. cSBP was tonometrically estimated from the radial pulse wave using SphygmoCor software. Results: Over 4.1 years (median), 255 composite cardiovascular end points occurred. In multivariable bootstrapped analyses, cSBP thresholds (in mm Hg) of 110.5 (95% CI, 109.1–111.8), 120.2 (119.4–121.0), 130.0 (129.6–130.3), and 149.5 (148.4–150.5) generated 5-year cardiovascular risks equivalent to the American College of Cardiology/American Heart Association bSBP thresholds of 120, 130, 140, and 160. Applying 120/130 mm Hg as cSBP/bSBP thresholds delineated concordant central and brachial normotension (43.1%) and hypertension (48.2%) versus isolated brachial hypertension (5.0%) and isolated central hypertension (3.7%). With concordant normotension as reference, the multivariable hazard ratios for the cardiovascular end point were 1.30 (95% CI, 0.58–2.94) for isolated brachial hypertension, 2.28 (1.21–4.30) for isolated central hypertension, and 2.02 (1.41–2.91) for concordant hypertension. The increased cardiovascular risk associated with isolated central and concordant hypertension was paralleled by cerebrovascular end points with hazard ratios of 3.71 (1.37–10.06) and 2.60 (1.35–5.00), respectively. Conclusions: Irrespective of the brachial blood pressure status, central hypertension increased cardiovascular and cerebrovascular risk indicating the importance of controlling central hypertension.

Background Data regarding the efficacy of percutaneous coronary intervention (PCI) with new-designed drug eluting stent (new-DES) vs. bare metal stent (BMS) of saphenous vein grafts (SVG) stenosis is scarce. The primary objective was to compare 1-year clinical outcomes of PCI in stenosis of SVG using new-DES vs. BMS in a real-world population. Methods We carried out a multi-center registry comparing new-DES with BMS in all consecutive patients undergoing PCI of SVG. The primary composite endpoint was major adverse cardiac and cerebrovascular events (MACCE) at 1 year. This observation included 792 consecutive patients (mean age: 69 ±8.9 years), treated with either new-DES (n = 379, 47.9%) or BMS (n = 413, 52.1%). Results In unmatched cohort patients treated with new-DES vs. BMS had lower MACCE (28.3% vs. 21.4%, HR = 0.69, 95% CI: 0.50–0.95, p = 0.025) as well as myocardial infarctions (MI) (12.1% vs. 6.3%; HR = 0.49, 95% CI: 0.30–0.82, p = 0.005) at 1 year. After propensity score matching similar, significant reduction in MACCE and MI was sustained in new-DES vs. BMS groups (HR = 0.66, 95% CI: 0.46–0.96, p = 0.030; and HR = 0.53, 95% CI: 0.31–0.92, p = 0.020, respectively). Conclusions In patients undergoing PCI of SVG, the use of new-DES is associated with a reduced 1-year rate of MACCE and MI compared to BMS., Background Presence of durable polymers may be associated with late/very late stent thrombosis occurrence and the need for prolonged dual antiplatelet therapy. Bioresorbable polymers may facilitate stent healing, thus enhancing clinical safety. Aim We sought to determine the 3-year clinical follow-up in patients treated with the thin strut (71 μm) bioabsorbable polymer-coated sirolimus-eluting (BP-SES) stent versus durable coating everolimus eluting stent (DP-EES) in daily clinical routine. Methods Interventional Cardiology Network Registry is a multicenter, all-comers registry of 21.400 patients treated with PCI between 2010 and 2016. All patients who underwent implantation of either ALEX (n = 287) or XIENCE (n = 1114) stents within a time frame of availability of 3-year clinical follow-up were included. We evaluated the incidence of all-cause deaths at 3-year follow-up and a composite endpoint of death or myocardial infarction. Results There was no significant differences between the groups in procedure related complications and in-hospital mortality (ALEX 1.8% vs. XIENCE 1.0%, p = 0.22). Follow-up demonstrated similar 3-year all-cause mortality (ALEX 12.0% vs. XIENCE 11.9%, p = 0.99), as well as comparable incidence of composite endpoint in ALEX group when compared to XIENCE (19.9% vs. 20.0%, p = 0.98, respectively). Conclusions In this multicenter registry, ALEX stent demonstrated comparable clinical outcomes at 3 years after implantation to the XIENCE stent. These data support the relative long-term safety and efficacy of ALEX in a broad range of patients undergoing percutaneous coronary interventions., Background Peri-strut low intensity areas (PLIA) surrounding metallic stents struts, visualized by optical coherence tomography (OCT) images, have been related to inflammation, neointimal proliferation and increased incidence of target lesion revascularization. Aim To determine the association between PLIA by OCT and the vascular healing response after bioresorbable scaffold (BRS) implantation in the setting of acute myocardial infarction (MI). Methods This is a single-centre, longitudinal study with a serial: baseline, 12- and 24-month OCT evaluation of neointimal response after percutaneous coronary intervention (PCI) with BRS implantation in patients presenting with ST-segment elevation MI (STEMI). Neointimal thickness and area were evaluated in relation to the presence of PLIA by OCT. Every analyzed cross section was scored: 0 – no PLIA; 1 – PLIA in < 1 quadrant; 2 – PLIA in 1 but < 2 quadrants; 3 – PLIA in 2 but < 3 quadrants; 4 – PLIA in ≥ 3 quadrants. A total of 18 STEMI patients treated with 20 AbsorbBRS implantation were included. Results The presence of PLIA within the scaffolds was identified in 55%. The significant positive correlation was found between PLIA score and the mean (r = 0.406; p = 0.038), maximal (r = 0.421; p = 0.032) and minimal neointimal thickness (r = 0.426; p = 0.03), but not with neointimal area (r = –0.091; p = 0.352) after 24 months. No difference was observed between the PLIA positive and negative group in terms of the neointimal thickness and area. Conclusion In STEMI patients treated with BRS implantation, presence and extent of PLIA by OCT may be associated with the pattern of neointimal formation. This surrogate parameter may serve as a tool for evaluation of in-scaffold neointimal growth after future generation BRS implantation. Figure 1 Peri-strut low intensity area (PLIA) score classification on the optical coherence tomography (OCT). The analyzed cross sections were scored: 0 – no signs of PLIA; 1 if PLIA in < 1 quadrant; 2 if PLIA in 1 but < 2 quadrants; 3 if PLIA in 2 but < 3 quadrants; and 4, if PLIA in ≥ 3 quadrants, Background The biodegradable polymer drug-eluting stents were developed to improve vascular healing. However, further data is needed to confirm the safety and efficacy of these stents in patients with acute myocardial infarction (AMI). Aim We sought to determine the 1-year clinical follow-up in patients with AMI treated with the thin strut biodegradable polymer-coated sirolimus-eluting (BP-SES) stent versus durable coating everolimus-eluting stent (DP-EES). Methods We analyzed patients with AMI (STEMI and NSTEMI) treated with either a BP-SES (ALEX™, Balton, Poland, n = 886) or DP-EES (XIENCE™, Abbott, USA, n = 1054) with available 1-year clinical follow-up using propensity-score matching. Outcomes included target vessel revascularization (TVR) as efficacy outcome and all-cause death, myocardial infarction, and definite/probable stent thrombosis as safety outcomes. Results After propensity score matching 672 patients treated with BP-SES and 672 patients treated with DP-EES were selected. Procedural and clinical characteristics were similar between both groups. In-hospital mortality was similar in both tested groups. One-year follow-up demonstrated comparable efficacy outcome TVR (BP-SES 7.1% vs. DP-EES 5.2%, p = 0.14), as well as similar safety outcomes of all-cause death, myocardial infarction, and definite/probable stent thrombosis. Conclusions The thin-strut biodegradable polymer coated sirolimus-eluting stent demonstrated comparable clinical outcomes at 1-year after implantation to the DP-EES. These data support the relative safety and efficacy of BP-SES in high-risk ACS patients undergoing PCI., Background Myocardial infarction with non-obstructive coronary arteries (MINOCA) remains still challenging mainly due to its complex and multiple etiology. Aim To assess the relationship between gender and clinical outcomes during follow-up in patients after MINOCA and predictors of main adverse cardiac and cerebrovascular adverse events (MACCE). Methods The study consisted of 134 patients (78 females, 58.2%) at the mean age of 61.6 years who were diagnosed with MINOCA in our department of cardiology within the period from January 2015 to June 2018. The subjects were included in the average follow-up period lasting 609.5 days. The primary study endpoints were MACCE, which included death, myocardial infarction, reintervention and cerebral stroke. The evaluated secondary study endpoints were recurrent chest pains in the follow-up period and rehospitalization for reasons other than MACCE. Additionally, we assessed predictors of primary and secondary study endpoints. Results The MINOCA frequency is presented in Figure 1. Kaplan Meier survival curve analysis did not reveal statistically significant differences in the frequency of MACCE (p = 0.63) or mortality rate (p = 0.29) between males and females during follow-up period. There was no statistically significant impact of gender on secondary study endpoints during the follow-up. Univariate and multivariate analysis of predictors of primary and secondary study endpoints has not included gender among other confirmed predictors of clinical outcomes during follow-up in patients after MINOCA. Figure 1 MINOCA frequency stratified by sex and year of enrollment Conclusions Despite a number of clinical differences and comorbid diseases between genders in patients after MINOCA, gender was not found to be significantly associated with clinical outcomes during the follow-up., Background Frailty syndrome (FS) is an exponent of advanced biological age and an important risk factor for the development of adverse outcomes. The multi-factor cascade of the change process should be considered in the context of both biological and psychological as well as socio-environmental factors. In connection with the above, it is indicated increasingly the importance of a new phenomenon which is cognitive impairment (CI) associated with co-existing FS, so-called cognitive frailty (CF). The heterogeneity of FS and CI is one of the risk factors for cardiovascular events. This can be extremely important in elderly patients with the acute coronary syndrome (ACS) because patients with CF may not meet the therapeutic goals. Aim To describe the association between FS and CI in elderly patients with ACS. Methods This prospective observational study included one-hundred patients aged 65 or older hospitalized for ACS. Frailty was assessed using the Tilburg Frailty Indicator (TFI). The Mini-Mental State Examination (MMSE) was used for cognitive function evaluation (study results are presented in Tables I-IV). Table I Characteristics of participants Mean (SD) Median (min.-max.) P-value 76.08 (8.24) 77 (68–84) 0.004 Mean age of women = 78.43 years old, mean age of men = 73.87 years old. Table II Results of the TFI questionnaire TFI Women (n = 48) Men (n = 52) All (n = 100) P-value n % n % n % Frail 36 73.47 24 46.15 60 60.00 0.01 No frail 12 25.00 28 53.85 40 40.00 The mean total TFI score = 6.98. Table III Cognitive impairment in patients with frailty syndrome FS CI (n = 40) No CI (n = 60) P-value n % n % Frail 36 90.00 24 40.00 < 0.001 No frail 4 10.00 36 60.00 Females 50% > Males 30%. Table IV Domain of the TFI questionnaire in patients with cognitive impairment Domain CI N Mean SD Median Min. Max. Q1 Q3 P-value* Physical + 40 6.17 1.52 6 2 8 5.75 7 < 0.001 – 60 3.48 2.08 3 0 8 2 5 Psychological + 40 2 0.93 2 0 3 1 3 0.001 – 60 1.28 0.98 1 0 3 1 2 Social + 40 0.92 0.86 1 0 3 0 1 0.655 – 60 0.8 0.68 1 0 2 0 1 Conclusions Cognitive frailty occurred in the studied population of patients with ACS. There is a negative relationship between the presence of FS (especially in the physical and psychological domain of the TFI) and CI. It is worth mentioning that there is still a lack of sufficient studies on the cognitive frailty in patients with ACS. The obtained results may be helpful in optimizing the care plans and implementing interventions to improve physical and psychological functioning in patients with co-existing cognitive frailty., Background Profilin 1 (Pfn 1) is a small protein crucial in the regulation of actin cytoskeleton. Several studies show it may play a role in gene expression and intracellular communication, being released from platelets and possibly other cells (endothelium, leukocytes). An increasing amount of data suggests Pfn 1 is a key player in the pathogenesis of stable angina and acute coronary syndrome. A basic factor influencing the treatment and prognosis of patients with type 1 myocardial infarction (t1MI) is the duration of symptoms of ischemia. In everyday clinical practice, it is often difficult to determine this parameter, due to a number of patient-related factors (e.g. unclear symptom onset, stress, etc). Therefore, it is reasonable to search for a laboratory indicator of symptom duration. Methods 65 patients with t1MI (STEMI or NSTEMI) treated with pPCI were enrolled in the study. The exclusion criteria were: inability to define the time of symptom onset; symptom duration > 24 h; s/p CABG; active inflammation; any thrombosis, stroke or MI within the last 3 months; neoplasms; hypercoagulability; stage 4 or 5 chronic kidney disease. Pfn 1 concentration in peripheral blood was assessed using an enzyme-linked immunosorbent assay (ELISA) in three time points: on admission, 24 and 48 h post pPCI. Results We found a negative correlation between symptom duration and Pfn 1 concentration on admission (Spearman R = –0.42, p = 0.008), 24 h post pPCI (Spearman R = –0.30, p = 0.022) and 48 h post pPCI (Spearman R = –0.28, p = 0.033). Patients presenting with symptoms lasting less than 6 h had a significantly higher concentration of Pfn 1 than those with symptoms lasting longer than 6 h (838.54 vs. 687.12, p = 0.007). Conclusions To our knowledge, this is the first study investigating the relationship between Pfn 1 and symptom duration in both STEMI and NSTEMI patients. We have shown that Pfn 1 concentration in peripheral blood is inversely proportional to symptom duration, probably due to release from activated platelets during intracoronary thrombus formation. Pfn 1 may be an objective indicator of the symptom duration in MI, and as such could be a a valuable tool in decision-making and prognostic assessment., Background Epidemiology of valvular hearth defects has changed in recent years. Aging of the population has contributed to the increase of the percentage of both, degenerative defect and coronary heart disease. Due to the lack of current data on coronary artery disease among patients with valvular diseases in Podlaskie region this study gathers information about this group of patients. Aim The analysis of the atherosclerotic plaque burden distribution in the coronary arteries and long term prognosis among patients with valvular heart disease. Methods Retrospective analysis considered medical documentation of 12954 patients hospitalized in the Department of Invasive Cardiology of the Medical University of Bialystok. Follow-up of total morality was done after the average of 1500 days. Results Valvular heart disease was diagnosed in 1214 patients, among whom 843 subjects had coronary artery disease. Mitral regurgitation was the most common valvular defect, which, at different severity grading, occurred at 50% of the studied population (n = 607). The most common severe valvular heart defect was aortic valve stenosis, which affected 23% of patients (n = 279). Combined valvular heart disease occurred in 44.7% patients (n = 543), of which 29.5% (n = 358) had a disease of more than one valve. Significant coronary artery narrowings were diagnosed in 524 patients. Angiographicaly significant stenoses were mostly reported in LAD (25.25%, n = 303), Cx, (23.91%, n = 287) and RCA (23.66%, n = 284). There were 236 percutaneous coronary interventions (19,6%), with the prevailing PCI of Cx (n = 139) and LAD (n = 93). The operation due to valvular heart defects was performed in 47.98% patients, and 41.06% of those underwent coronary artery bypass surgery. Significant stenosis of the right coronary artery was more frequently diagnosed among patients who died (21.77% vs. 31.38%, p < 0.001). Subjects with severe mitral valve insufficiency more often presented with the diagonal artery stenosis. Conlcusions The most common defect in the analysed population was mitral regurgitation of all grading severity. Aortic valve stenosis was the most severe valvular heart defect and presented with significantly worse prognosis comparing to other heart diseases despite lower risk of death. Coronary artery disease was an additional factor worsening the prognosis of patients with heart defects. More than 50% of patients underwent coronary revascularization. Significant stenosis of diagonal artery more frequently occurred in mitral insufficiency, and significant stenosis of right coronary artery worsened the prognosis. During 8-year follow-up 19.7% of subjects died., Background Both IVUS and FFR are been used to assess the clinical importance of a borderline coronary lesion. It has been suggested that more lesions are significant when assessed using IVUS than when using FFR. Methods Consecutive pts with borderline, de novo coronary lesions (%DS ≥ 40%, but < 70%) from the ANIN IVUS & FFR registries were analyzed. Cut-off values of significance were an IVUS minimum lumen area (MLA) < 3.0 mm2 and minFFR < 0.8. Results Between 1/2009 to 12/2016 there were 1225 patients with 1547 borderline lesions (880 IVUS; 667 FFR). IVUS was almost exclusively preferred for left main (LM) lesions (p < 0.001); but other coronaries were examined with both techniques equally (Figure 1). After exclusion of 408 pts with LM lesions, those examined with FFR were significantly older, had more hypertension and hyperlipidemia, but had less previous PCI. Mean MLA was 4.2 ±1.8 mm2, and mean minFFR was 0.83 ±0.09. Overall, 31.8% of LAD lesions were significant because of an IVUS MLA < 3.0 mm2 or an minFFR < 0.8 vs. 19.5% in RCA and 21.2% in LCx (p = 0.001). More lesions were significant by FFR vs. IVUS (32.6% vs. 23.9%; p = 0.002), especially in the LAD; whereas RCA lesions were considered significant more frequently by IVUS, and LCx lesions were significant with similar frequency by both techniques (Figure 1). Figure 1 Distribution of IVUS, FFR, MLA < 3.0 mm2 and FFR < 0.8 among the coronary arteries Conclusions The saying “If you want to treat, use IVUS. If you don’t, use FFR” is clinically untrue using contemporary criteria, especially when recognizing specific vessel differences. Use of IVUS for borderline verification does not lead to more intervention as compared to FFR assessment., Background Stress perfusion CMR or SPECT are used for assessment of myocardial ischemia. Methods Consecutive pts in whom induced ischemia (expressed as a % of left ventricular (LV) mass) was established using SPECT (SYMBIA INTEVO EXCEL) or MR (1.5T scanner, Philips Gyro-Scan NT) with different methods of inducing stress were analyzed and compared. Results From 2013 to 2017, 696 patients (65.2 years; 29.0% males) were studied with CMR; from 2016 to 2017, 690 patients (66.5 years; 31.0% males) were studied with SPECT. Ischemia of any level was more frequently identified using SPECT vs. CMR (72.3% vs. 31.5%; p < 0.001). However, total ischemia burden was greater with CMR vs. SPECT (10% (9% to 15%) vs. 5% (3% to 6%); p < 0.001). Also, ≥ 10% ischemia was identified more frequently with CMR vs. SPECT (22.7% vs. 9.6%; p < 0.001) and more frequently with dipyridamole (p = 0.028, Figure 1). Comparing patients with inducible ischemia by SPECT vs. CMR, there were more patients with a history of chronic renal disease (14.9% vs. 8.2%, p = 0.004) and CABG (22.7% vs. 15.7%, p = 0.05), but less MI (43.9% vs. 53.6%, p = 0.033). There was no difference in hypertension, dyslipidemia, or diabetes. Patients with induced ischemia ≥ 10% were less often ≥ 65 years of age (51.3% vs. 61.8%, p = 0.048), but more often had diabetes (32.5% vs. 25.2%, p = 0.04) or an MI history (55.3% vs. 41.1%, p < 0.001). Figure 1 Distribution of the ischemia burden categorized with various cut-offs and assessed with different imaging modalities Conclusions SPECT is more sensitive in detecting any amount of ischemia, but CMR is more accurate in detecting pts with ≥ 10% LV involvement who have a worse prognosis. CMR identifies more often pts with ischemia involving more than 10% of LV mass while SPECT is a more sensitive technique for detecting the presence of ischemia., Background Even after all the workshop conditions of optimum angiography are fulfilled and even when working with high-resolution angiographic equipment, > 40% of borderline LM lesions have an inconclusive assessment. Methods In 2 orthogonal views (LAO vs. RAO) lumen diameters were measured among borderline LM lesions visualized at 15 f/s with the SiemensTM AXIOM (1024 × 1024 flat panel detector). Identified were the 3 frames within the narrowest region of LM lumenogram (1 back & 1 forward, counting from the one judged as the narrowest). Then, 3 independent measurements were made: minimal lumen diameter (3× MLD) and proximal & distal reference diameters (prox & dist ref diam, 3× each). Measurements were done with image enlarged by a factor of 2, using a dedicated digital caliper (plotting lines from a single pixel to a single pixel to the nearest 2 decimal places). Measurements and %DS (100% – MLD/mean ref diam) were categorized for their minimal and maximal values. Results Among the 32 consecutive patients (67 ±8 years, 53% males), 1567 diameters were measured. Absolute variations in min vs. max measured diameters as displayed on Figure 1. In a per patient analysis relative variations in measured diameters for prox ref, MLD and dist ref led to variations in min vs max %DS in LAO and RAO views of 30 ±14% vs. 49 ±14% (p < 0.001) and 32 ±17% vs. 55 ±13% (p < 0.001), respectively. Conclusions Even using contemporary coronary angiographic equipment, assessment of LM stenosis severity (as well as LM reference lumen size) is highly variable. The inherent limitations of angiography lead to inconsistency in LM stenosis severity assessment. Figure 1 Variations in measured minimal (solid) vs. maximal (transparent) diameters at the sites of: prox ref (◻), MLD (○) and dist ref (◊) (on a per frame (A) & per patient basis (B)) (p < 0.001 for all corresponding comparisons of min vs. max), Background In primary care, 10–20% of people complain of significant sleep problems, with nearly 100 identified types of sleep disorders. A number of factors lead to under-detection of sleep deprivations. Its effective diagnosis is important to receive the correct treatment. Aim To proposed original concept of the infrastructure of the home-care system for sleep identification and sleep event scoring (Figure 1). Figure 1 Block diagram summarizing the steps followed in this study, from signal recording to the biostatistical and Information Theory based analysis Methods This study includes some preliminary results toward ECG-based diagnosis of sleep disorders. Sleep deprivation detection problem is modeled as a two-group classification problem. The two subject groups are: healthy individuals and Sleep Related Breathing Disorders (SRBD) positives (12 subjects). Parameters derived from ECG and acoustic analysis were considered as input for the predictive statistical models used to find the best possible classification of sleep disorders. Moreover, as an alternative to statistical analysis Lempel-Ziv Complexity (LZC) algorithm as detection tool of sleep deprivation via ECG was applied. Results Our results show that the best events recognition is reached for over 89% (raw database) and for over 92% (up-sampled database) good predictions. It turned also out, that the SRBD patients have more regular ECGs, which are characterized by LZC around 0.32, while control group has the complexity around 0.85 and variability of patterns is much larger. Conclusions Proposed diagnostic method, which links biostatistics with Information Theory approach, is a powerful tool for the classification of sleep disorders, even in the early stage. It provides also inspiring insight into developing effective algorithms of telemedical data interpretation., Background Coarctation of the aorta (CoA) is a common cause of secondary arterial hypertension (HTA). Aim To analyze the diagnostic route and medical therapy of HTA in a series of adults undergoing endovascular stenting of CoA. Methods Twenty-four consecutive adults (median age: 36 years, 15 men) were enrolled. Clinical history was collected at baseline, wherein special attention was paid to the time period between onset of HTA and diagnosis of CoA. Patients were contacted by phone after 34 ±17 months to follow up medical treatment. Results The mean age at detection of HTA was 17.1 ±8.8 years (range: 1–36 years), while the mean age at diagnosis of CoA was 33.5 ±14.9 years (range: 1–77). The mean delay in diagnosis was 16.4 ±11.1 years (maximally 37). All patients underwent successful CoA stenting with excellent trans-coarctation gradient reduction (40.1 ±15.9 before the procedure vs. 1.3 ±2.2 mm Hg after the procedure; p < 0.001; 95% CI: 32.1–45.4). No early complications were observed; in 1 case redo intervention was performed due to aortic aneurysm formation. Overall, 95.8% of patients received antihypertensive treatment at baseline (79.2% with ≥ 3 drugs), compared to 65.2% at follow-up (30.4% with ≥ 3 drugs); p = 0.008, Z = –2.65. The mean number of antihypertensives dropped from 3.1 ±1.3 to 1.9 ±1.7 (p < 0.001; 95% CI: 0.67–1.94). The mean number of reduced drugs per patient was 1.3 ±1.4 (Table I). Table I Detailed characteristics of the patients enrolled Patient Sex Age at the intervention [years] Delay in the diagnosis [years] SBP/DBP [mm Hg] Number of antihypertensive drugs Invasive PG [mm Hg] Before stenting After stenting Baseline Follow-up Before stenting After stenting 1† F 77 n/a 140/90 n/a 4 n/a 39 3 2 M 46 10 130/80 130/80 5 5 58 1 3$,# F 26 < 1 140/90 130/70 3 0 25 5 4# M 18## 2 200/120 140/70 2 4 60 6 5 F 41 1 175/84 120/70 3 2 51 4 6 M 30 4 170/75 117/69 5 3 28 0 7 F 35 11 208/87 133/79 3 0 49 1 8 M 26 10 145/80 129/77 3 0 45 0 9* F 35 n/a 162/93 123/76 3 1 48 0 10 M 38 21 169/102 154/109 3 2 70 0 11$ M 41 < 1 170/80 164/96 3 2 62 4 12 M 37 19 175/77 151/91 6 4 33 3 13 F 38 29 135/70 101/73 0 0 39 0 14 M 38 36 150/84 135/70 3 2 25 0 15 M 30 17 182/82 162/84 3 4 18 0 16 M 47 12 131/75 132/75 4 0 39 3 17* F 27 n/a 117/76 101/70 1 0 30 3 18 M 60 30 173/85 120/82 3 0 26 0 19 F 35 16 148/81 122/78 3 2 14 1 20** M 31 n/a 158/68 135/72 4 5 34 1 21 F 27 14 146/84 129/86 2 0 27 0 22** M 41 n/a 144/84 105/67 4 2 24 2 23 M 29 16 144/79 148/77 1 1 67 0 24 M 45 37 149/89 135/87 4 4 57 1 M – male, F – female, SBP – systolic blood pressure, DBP – diastolic blood pressure, PG – pressure gradient, n/a – not available/not applicable † intra-hospital death $ prompt diagnosis of CoA # treated with a bare metal stent ## age at the original intervention * diagnosed in infancy, not operated, ** diagnosed and operated in infancy. Conclusions Delayed diagnosis of CoA leads to unnecessary antihypertensive medication, therefore diagnostics focused on CoA should be carried out in all children and young adults presenting with HTA. Endovascular stenting is a safe and effective treatment strategy for CoA in adults that significantly improves medical treatment.

PubMed: 30270054, 2-s2.0-85053666909, Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ?2/3 countries. Lipoprotein-apheresis is offered in ?60% countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed. © 2018 Elsevier B.V., Universidade de São Paulo, USP European Atherosclerosis Society, EAS Amgen Merck Sharp and Dohme, MSD, The ELSA Study suggests heterozygous FH (HeFH) may affect 1:263 Brazilians (?766,000 individuals). Currently, the only active genetic cascade screening program in Brazil is Hipercol Brasil in Sao Paulo (genetic testing for adults with low-density lipoprotein cholesterol (LDL-C) ?230?mg/dL, to maximise cost-effectiveness), with 1719 heterozygotes, 25 homozygotes, 13 compound-heterozygotes and one double-heterozygote identified by March 2018. To date, 4340 individuals from 440 families were screened. Genetic testing is funded by a government tax reduction programme (PROADI-SUS), and cascade screening by partnering between Samaritano Hospital and Heart Institute (InCor) University of Sao Paulo. Most FH patients are under non-specialist care and currently under-treated., Prevalence is unknown but assumed at 1:250. There is no state programme and few patients were diagnosed before the Latvian FH Registry was established in 2015. To date, the Registry has identified 181 cases (2.3% of 7876 estimated HeFH cases; no HoFH). Cascade screening is performed in first-degree relatives of index cases with probable/definite FH. Genetic testing is not reimbursed but has been funded by research grants for a few patients/relatives. About 5% of patients had LDL-C at target before inclusion in the Registry [ 61 ]. Statins are reimbursed 50% in primary prevention; statins and ezetimibe, 75–100% in secondary prevention; PCSK9i are available, but not reimbursed., Estimated prevalence is 1:250 (based on a meta-analysis of 6 observational studies) or 136,300 adults (only 2% diagnosed) [ 69 , 70 ]. Based on LIPIDOGRAM studies (2004–2015, ?50,000 participants), prevalence might be?1:200 [ 71 , 72 ]. Five HoFH cases are described [ 73 , 74 ]. Patients with DLCN ?3 are referred for genetic testing, funded by the National Health Program. The National Centre for FH at University Clinical Hospital, Medical University of Gdansk, was established in 2017, financed by the Ministry of Health. From August 2017, 345 patients underwent genetic testing (153 positive, including 46 relatives; 1 HoFH). Since 1999, 1884 patients (562 families) have undergone genetic testing and cascade diagnosis (data from the National Polish FH Registry, Medical University of Gdansk, established in 2000). PCSK9i are not reimbursed (under discussion with the Ministry of Health)., The EAS FHSC project has received support from a Pfizer Independent Grant for Learning & Change 2014 (No: 16157823 ) and from investigator-initiated unrestricted research grants to the European Atherosclerosis Society from Amgen , MSD , and Sanofi-Aventis .